Inflammatory disease Archives

News and Trends 31 Jul 2023

Biogen acquiring Reata Pharmaceuticals for $7.3B

Biogen Inc. and Reata Pharmaceuticals, Inc. have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value…

July 31, 2023 - 3 minutesmins - By Jim Cornall

Podcast 20 Jul 2023

Beyond Biotech podcast 55: Inflammasomes

This week on our podcast, we’re talking about inflammasome inhibitors with Alan Watt, CEO of NodThera. The company recently announced it is the first to show a reduction in neuroinflammation…

July 20, 2023 - 2 minutesmins - By Jim Cornall

Dr. Grégoire Stik, group leader at the Josep Carreras Leukaemia Research Institute and co-author of the study.

News and Trends 11 Jul 2023

Immune memory research could lead to next generation of epigenetic drugs

A team of researchers has discovered that the memory of the immune system relies on characteristic epigenetic features and a specific 3D arrangement of the DNA in the nucleus of…

July 11, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 11 Jul 2023

NodThera first to show reduction in neuroinflammation with inflammasome inhibitor

NodThera has announced positive, initial data from four subjects in the elderly volunteer stage of its phase Ib/IIa study evaluating the effects of its lead candidate NT-0796 on inflammatory and…

July 11, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 20 Jun 2023

NodThera announces positive inflammatory disease data

NodThera has announced positive data from first-in-human studies of its lead therapeutic candidates, NT-0249 and NT-0796. In the studies, both candidates were shown to clearly inhibit the NLRP3 inflammasome, a…

June 20, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 May 2023

Diagnosing inflammatory diseases with synthetic peptides

Common inflammatory disorders such as ulcerative colitis and Crohn's disease can be diagnosed or monitored by measuring the protein calprotectin in stool samples, while serum levels of calprotectin could be…

May 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 9 May 2023

Gilead boosts oncology pipeline with XinThera acquisition

Gilead Sciences, Inc. has announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. Gilead Sciences said the acquisition complements its existing clinical…

May 9, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 27 Apr 2023

Patients with asthma and other inflammatory lung diseases can be treated ‘in a fundamentally new way’

Arrowhead Pharmaceuticals Inc. has announced interim results from an ongoing phase 1/2 clinical study of ARO-RAGE, an investigational RNA interference (RNAi) therapeutic designed to reduce production of the receptor for…

April 27, 2023 - 3 minutesmins - By Jim Cornall

Podcast 14 Apr 2023

Beyond Biotech podcast 41: Sarcoidosis

This week, to coincide with World Sarcoidosis Day, we talk about sarcoidosis with Marcin Szumowski, CEO and president of the management board of Molecure. World Sarcoidosis Day As part of…

April 14, 2023 - 2 minutesmins - By Jim Cornall

Best in Biotech 15 Mar 2023

10 immunotherapy companies making waves in 2023

Immunotherapy has been widely studied in cancer treatment research, ever since William Coley, who is regarded as the father of immunotherapy, first attempted to leverage the immune system for oncological…

March 15, 2023 - 10 minutesmins - By Roohi Mariam Peter

News and Trends 3 Mar 2023

Orphan drug designation for Laevoroc metabolic immune checkpoint inhibitor

Laevoroc Immunology, a privately-owned, Swiss oncology development company, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for immune checkpoint inhibitor LR 09. LR…

March 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

Positive topline data from sepsis trial

Modus Therapeutics AB has published positive top-line data from its phase 1b lipopolysaccharide (LPS) provocation study, a key step in evaluating the potential of its lead asset, sevuparin, as a…

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

Certa scleroderma study shows improvement in more than 60% of patients

Certa Therapeutics has announced what it says are ground-breaking clinical trial data for FT011, its novel therapy for the treatment of serious inflammatory and fibrotic diseases. Certa Therapeutics has recently…

February 7, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 27 Jan 2023

FDA clearance for ‘revolutionary’ approach to J-Pouch issue

ExeGi Pharma LLC, which develops live biotherapeutic drugs and probiotics, says the FDA has cleared its Investigational New Drug (IND) application for its biologic drug candidate, EXE-346. The clearance allows…

January 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 26 Jan 2023

Lupus treatment hope from Japanese miRNA research

A group of researchers from the Graduate School of Medicine at Nagoya University in Japan have discovered the impact of microRNA (miRNA) on inflammation in lupus in mice. They identified…

January 26, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 24 Jan 2023

CytoReason expands deal with Sanofi to look at IBD

CytoReason, which creates computational disease modeling, has announced an expansion of its collaboration with Sanofi. The multi-year collaboration will further fuel Sanofi’s target discovery efforts via CytoReason’s AI platform in…

January 24, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 12 Jan 2023

Anticancer drugs could lead to new sepsis treatment

Researchers at the Instituto Gulbenkian de Ciência (IGC) in Oeiras, Portugal, say because anti-cancer drugs limit inflammation, they could be a potential treatment for sepsis. The study, published in eLife,…

January 12, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 22 Dec 2022

Positive Dupixent eosinophilic esophagitis phase 3 results

The New England Journal of Medicine has published results from a positive phase 3 trial showing adults and adolescents treated with Dupixent (dupilumab) 300 mg weekly experienced significant improvements in…

December 22, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 7 Dec 2022

Apogee Therapeutics raises $169M to tackle immunological and inflammatory disorders

Apogee Therapeutics, LLC, a biotech company advancing novel, potentially best-in-class therapies to address immunological and inflammatory disorders, has announced the closing of a $149 million Series B financing. Proceeds will…

December 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 6 Dec 2022

Tetra announce significant results from the study of Onternabez combined with Favipiravir

Tetra Bio-Pharma Inc. a leader in cannabinoid-derived drug discovery and development announced today significant results from the study of Onternabez combined with Favipiravir. The combination acts against ARDS (acute respiratory…

December 6, 2022 - 2 minutesmins - By Liza Laws

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Register for the Webinar

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering